While circulating cell-free DNA (ccfDNA) and to some extent circulating tumor cells (CTCs) from blood are routinely used as analytes in liquid biopsy cancer research applications, circulating cell-free RNA (ccfRNA) has recently also gained relevance for biomarker studies. The combination of insights from different analytes promises an increase in the understanding of molecular processes in tumor biology. However, there are challenges to overcome in the preanalytical workflow such as defining suitable blood collection tubes for optimal assay sensitivity.
In this presentation, the featured speaker shows the multianalyte use of the PAXgene Blood ccfDNA Tube (RUO) for plasma extraction as part of a liquid biopsy workflow.
Join this webinar to learn more about optimizing liquid biopsy workflow for better assay sensitivity with multianalyte applications.
Dr. Andrea Huxhold, Senior Global Market Manager (PreAnalytiX) and Co-Author of presented publication on assay sensitivity, QIAGEN/PreAnalytiX
Dr. Andrea Huxhold is a Senior Global Marketing Manager and joined QIAGEN in 2014 as a Product Development Scientist at the joint venture with BD, PreAnalytiX. She developed the PAXgene Blood ccfDNA Tube and QIAsymphony PAXgene Blood ccfDNA Kit including further research applications of this workflow. Prior to joining QIAGEN Andrea graduated from Philipps University Marburg as Human Biologist and earned her PhD in the Institute of Biochemistry and Molecular Biology at University Clinic in Aachen, Germany.Message Presenter
Who Should Attend?
Senior professionals from biopharma, biobanks, companion diagnostics, sales & marketing, technology transfer and CROs who are:
- Lab Supervisors/Managers/Directors
- Physicians/Healthcare Professionals/Basic Researchers
- Staff Scientists
- Purchasing Managers/Agents
- Assay Providers
- Market Development Managers
What You Will Learn
Attendees will gain insights into:
- The need of standardized workflows
- The need for blood stabilization for cell-free DNA (ccfDNA) analysis and impact on assay sensitivity
- The multianalyte applications for liquid biopsy research
PreAnalytiX, a joint venture between BD and QIAGEN, develops, manufactures and sells integrated and standardized systems for sample collection, stabilization and purification of high-quality RNA, microRNA and DNA from human blood, bone marrow, or tissue specimens. The Company serves healthcare institutions, academic researchers, clinical laboratories and the pharmaceutical industry with a broad array of manual and automated products.
QIAGEN is the leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. QIAGEN sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective molecular testing workflows. QIAGEN provides these workflows to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Further information can be found at http://www.qiagen.com.